FDA approves Geron’s RYTELO for the treatment of adults with lower-risk MDS with transfusion-dependent anemia
The U.S. Food and Drug Administration (FDA) has approved Geron Corporation’s RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent (TD) anemia requiring four or …